The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Mereo BioPharma Group plc(NASDAQ:MREO) 
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and IT...
Website: http://www.mereobiopharma.com/
Founded: 2015
Full Time Employees: 50
CEO: Denise Scots-Knight
Sector: Healthcare
Industry: Biotechnology
Mereo BioPharma Group plc Number of Twitter Followers
Mereo BioPharma Group plc Days Payable Outstanding ttm (DPO)
Mereo BioPharma Group plc Days Receivable Outstanding ttm (DSO)
Mereo BioPharma Group plc Days Inventory Outstanding ttm (DIO)
Mereo BioPharma Group plc Op Cashflow Per Share ttm
Mereo BioPharma Group plc Free Cashflow Per Share ttm
Mereo BioPharma Group plc Cash Per Share ttm
Mereo BioPharma Group plc P/S ratio ttm
Mereo BioPharma Group plc (GAAP) P/E ratio ttm
Mereo BioPharma Group plc P/B ratio ttm
No extra charts and metrics for this ticker.